Antioxidant, Acetyl- and Butyrylcholinesterase Inhibitory Activities of a Memory Enhancer Formulation from Traditional Persian Medicine (TPM)

Document Type : Original Article

Authors

1 Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Phytopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences.

3 Department of Pharmacognosy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/tips.2025.107477.1305

Abstract

Alzheimer's (AD) is the most common type of dementia in humans. The cholinergic hypothesis is one of the most important theories behind the pathogenesis of AD. It claims that excessive activity of the enzyme acetylcholinesterase causes the degradation of acetylcholine, which reduces its concentration in the brain and leads to dementia symptoms. AD ("Nesyan" in ancient Persian = forgetfulness) has been thoroughly investigated in Persian medicine. Various remedies have been recommended for the prevention, treatment, and symptom management of AD. One prescribed polyherbal formulation, Safoof-e-Nesyan (SEN), includes Cinnamomum verum bark, Zingiber officinale rhizome, Boswellia carterii gum, Acorus calamus rhizome, Syzygium aromaticum flower, Cinnamomum cassia bark, and Cyperus rotundus rhizome. This study investigates the effect of this formulation on the acetylcholinesterase and butyrylcholinesterase activities and its antioxidant effects. Methanol and dichloromethane extracts of each component and the whole formulation were prepared. DPPH free radical assay revealed the lowest IC50 value (13.0±1.03 µg/ml) for A. calamus dichloromethane extract. The results of the enzyme inhibition assays showed that SEN could be considered an enzyme inhibitor. Also, methanol extracts showed a more substantial effectiveness than dichloromethane extracts. Results indicated the highest inhibition of S. aromaticum, B. carterii, and C. verum against acetylcholinesterase. Contrary to this, the highest inhibition of butyrylcholinesterase enzyme activity was attributed to C. rotundus, S. aromaticum, and A. calamus extracts, which are responsible for the manifestation of anti-AD activity of the present formulation.

Highlights

Mohammad Ali Farboodniay Jahromi (Google Scholar)

Mahmoodreza Moein (Google Scholar)

Mohammad M. Zarshenas (Google Scholar)

Keywords

References

1.    Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer's disease. Signal Transduct Target Ther. 2019 Aug 23;4:29. doi: 10.1038/s41392-019-0063-8. Erratum in: Signal Transduct Target Ther. 2019 Sep 23;4:37. doi: 10.1038/s41392-019-0071-8. PMID: 31637009; PMCID: PMC6799833.
2.    Goel T, Sharma R, Tanveer M, Suganthan PN, Maji K, Pilli R. Multimodal Neuroimaging Based Alzheimer's Disease Diagnosis Using Evolutionary RVFL Classifier. IEEE J Biomed Health Inform. 2025 Jun;29(6):3833-3841. doi: 10.1109/JBHI.2023.3242354. PMID: 37022418.
3.    Licher S, Darweesh SKL, Wolters FJ, Fani L, Heshmatollah A, Mutlu U, Koudstaal PJ, Heeringa J, Leening MJG, Ikram MK, Ikram MA. Lifetime risk of common neurological diseases in the elderly population. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):148-156. doi: 10.1136/jnnp-2018-318650. Epub 2018 Oct 2. PMID: 30279211.
4.    Hendriks S, Peetoom K, Bakker C, van der Flier WM, Papma JM, Koopmans R, et al. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurol. 2021 Sep 1;78(9):1080-1090. doi: 10.1001/jamaneurol.2021.2161. PMID: 34279544; PMCID: PMC8290331.
5.    Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9. PMID: 29433981.
6.    Ruthirakuhan M, Lanctôt KL, Di Scipio M, Ahmed M, Herrmann N. Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. Alzheimers Dement. 2018 Oct;14(10):1344-1376. doi: 10.1016/j.jalz.2018.04.013. Epub 2018 Jun 23. PMID: 29940162.
7.    Zvěřová M. Clinical aspects of Alzheimer's disease. Clin Biochem. 2019 Oct;72:3-6. doi: 10.1016/j.clinbiochem.2019.04.015. Epub 2019 Apr 26. PMID: 31034802.
8.    Gabin JM, Tambs K, Saltvedt I, Sund E, Holmen J. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study. Alzheimers Res Ther. 2017 May 31;9(1):37. doi: 10.1186/s13195-017-0262-x. PMID: 28569205; PMCID: PMC5452294. 
9.    Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000 Aug;7(4):321-31. doi: 10.1006/nbdi.2000.0304. Erratum in: Neurobiol Dis 2000 Dec;7(6 Pt B):690. PMID: 10964604.
10.    Zhang Y, Tang Y, Zhang D, Liu Y, He J, Chang Y, Zheng J. Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes. Chinese J Chem Eng. 2021;30:225-235. doi:10.1016/j.cjche.2020.09.033. 
11.    Dake MD, De Marco M, Blackburn DJ, Wilkinson ID, Remes A, Liu Y, et al. Obesity and Brain Vulnerability in Normal and Abnormal Aging: A Multimodal MRI Study. J Alzheimers Dis Rep. 2021 Jan 20;5(1):65-77. doi: 10.3233/ADR-200267. PMID: 33681718; PMCID: PMC7903016.
12.    Abeysinghe AADT, Deshapriya RDUS, Udawatte C. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020 Sep 1;256:117996. doi: 10.1016/j.lfs.2020.117996. Epub 2020 Jun 23. PMID: 32585249.
13.    Kuo YC, Rajesh R. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Rev Neurother. 2019 Jul;19(7):623-652. doi: 10.1080/14737175.2019.1621750. Epub 2019 May 29. PMID: 31109210.
14.    Wu J, Pistolozzi M, Liu S, Tan W. Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2020 Mar 1;28(5):115324. doi: 10.1016/j.bmc.2020.115324. Epub 2020 Jan 18. PMID: 32008882.
15.    Amenta F, Battineni G, Traini E, Pallotta G. Choline-containing phospholipids and treatment  of adult-onset dementia disorders. In: Colin R Martin CR. and Preedy VR. (Eds). Diagnosis and  Management in Dementia. Elsevier, Inc., New York, 2020, pp. 477-493. doi:10.1016/B978-0-12-815854-8.00030-6.
16.    Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011 Aug;99(2):254-61. doi: 10.1016/j.pbb.2011.02.022. Epub 2011 Mar 5. PMID: 21382398; PMCID: PMC3114182.
17.    Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduct Target Ther. 2023 Jun 30;8(1):248. doi: 10.1038/s41392-023-01484-7. PMID: 37386015; PMCID: PMC10310781.
18.    Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003 Feb;4(2):131-8. doi: 10.1038/nrn1035. PMID: 12563284.
19.    Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J. 1989 Jun 15;260(3):625-34. doi: 10.1042/bj2600625. PMID: 2669736; PMCID: PMC1138724.
20.    Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 2002;110(4):627-39. doi: 10.1016/s0306-4522(01)00613-3. PMID: 11934471.
21.    Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies. Front Aging Neurosci. 2018 Mar 28;10:83. doi: 10.3389/fnagi.2018.00083. PMID: 29643804; PMCID: PMC5882872.
22.    Dou Y, Zhao D, Yang F, Tang Y, Chang J. Natural Phyto-Antioxidant Albumin Nanoagents to Treat Advanced Alzheimer's Disease. ACS Appl Mater Interfaces. 2021 Jul 7;13(26):30373-30382. doi: 10.1021/acsami.1c07281. Epub 2021 Jun 27. PMID: 34180234.
23.    Singh B, Day CM, Abdella S, Garg S. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024 Mar;367:402-424. doi: 10.1016/j.jconrel.2024.01.047. Epub 2024 Feb 1. PMID: 38286338.
24.    DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008 Nov 19;300(19):2253-62. doi: 10.1001/jama.2008.683. Erratum in: JAMA. 2008 Dec 17;300(23):2730. PMID: 19017911; PMCID: PMC2823569.
25.    Cristea R, Sandru DM. Investigating the Polyphenolic Profile and the Antioxidant and Antibacterial Activity of Tarragon (Artemisia dracunculus L) cultivated in Central Romania. Acta Chim Slov. 2023 Aug 21;70(3):345-352. doi: 10.17344/acsi.2023.8225. PMID: 40836542.
26.    Shah R. The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc. 2013 Jun;14(6):398-402. doi: 10.1016/j.jamda.2013.01.014. Epub 2013 Feb 16. PMID: 23419980.
27.    Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev. 2008;30:35-66. doi: 10.1093/epirev/mxn010. Epub 2008 Sep 8. PMID: 18779228.
28.    Lin HQ, Ho MT, Lau LS, Wong KK, Shaw PC, Wan DC. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease. Chem Biol Interact. 2008 Sep 25;175(1-3):352-4. doi: 10.1016/j.cbi.2008.05.030. Epub 2008 Jun 23. PMID: 18573242.
29.    Manyam BV. Dementia in Ayurveda. J Altern Complement Med. 1999 Feb;5(1):81-8. doi: 10.1089/acm.1999.5.81. PMID: 10100034.
30.    Taskin T, Öksüz M, Bulkurcuoğlu B, Ercelen S, Rayaman E, Ermanoğlu M, Yilmaz BN, Taskin D, Şahin T, Kılıç Ö. Chemical composition, in vitro and in silico biological activity of two Thymus L. varietes growing in Turkey. Acta Chim Slov. 2023 Dec 21;71(1):9-19. doi: 10.17344/acsi.2023.8314. PMID: 40836472.
31.    Rezaeizadeh H, Alizadeh M, Naseri M, Ardakani MS. The traditional Iranian medicine point of view on health and health. Iran J Public Health. 2009;38(Suppl.1): 169-172.
32.    L. Bayan, Mousavi Behbahani S.M.M, Gorji A. History of Neurological Disorders in Persian Medicine. Res Hist Med. 2013: 2(4):115-128.
33.    Hosseinkhani A, Sahragard A, Namdari A, Zarshenas MM. Botanical Sources for Alzheimer's: A Review on Reports From Traditional Persian Medicine. Am J Alzheimers Dis Other Demen. 2017 Nov;32(7):429-437. doi: 10.1177/1533317517717013. Epub 2017 Jul 6. PMID: 28683559; PMCID: PMC10852953.
34     Jamshidi AH, Eghbalian F, Mahroozade S, Ghobadi A, Yousefsani BS. Recommended natural products in Alzheimer's disease based on traditional Persian medicine. J Med Plants. 2020;19: 17-29. doi:10.29252/jmp.19.75.17.
35.    Marzabadi LR, Mohammadinasab R, Sha'rbaf JG, Araj-Khodaei M, Fazljou SM, Talebi M, Eteghad SS. Use of saffron against dementia and memory impairment in traditional Persian medicine: A historical perspective. Erciyes Med J. 2021;43(4):412-416. doi:10.14744/etd.2021.89248.
36.    Yousefsani BS, Barreto GE, Sahebkar A. Beneficial Medicinal Plants for Memory and Cognitive Functions Based on Traditional Persian Medicine. Adv Exp Med Biol. 2021;1308:283-290. doi: 10.1007/978-3-030-64872-5_20. PMID: 33861451.
37.    Nazem Jahan M. A., Gharabadin Azam (Lithgraphs in Persian).Tehran: Iran University ofMedical Sciences; 2004: 78-80.
38.    Sabahi Z, Zarshenas MM, Farmani F, Faridi P, Moein S, Moein M. Essential oil composition and in vitro antioxidant activity of ethanolic extract of Thymus daenensis Celak from Iran. Global J Pharmacol. 2013; 7(2): 153-158. doi:10.5829/idosi.gjp.2013.7.2.71124. 
39.    Ellman GL, Courtney KD, An­dres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88-95. doi: 10.1016/0006-2952(61)90145-9. PMID: 13726518.
40.    Heo JH, Eom BH, Ryu HW, Kang MG, Park JE, Kim DY, et al. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg. Sci Rep. 2020 Dec 10;10(1):21695. doi: 10.1038/s41598-020-78782-5. PMID: 33303801; PMCID: PMC7730441.
41.    Al Omairi NE, Al-Brakati AY, Kassab RB, Lokman MS, Elmahallawy EK, Amin HK, et al. Soursop fruit extract mitigates scopolamine-induced amnesia and oxidative stress via activating cholinergic and Nrf2/HO-1 pathways. Metab Brain Dis. 2019 Jun;34(3):853-864. doi: 10.1007/s11011-019-00407-2. Epub 2019 Mar 27. PMID: 30919246.
42.    Grabowska ME, Huang A, Wen Z, Li B, Wei WQ. Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review. Front Pharmacol. 2023 Sep 7;14:1257700. doi: 10.3389/fphar.2023.1257700. PMID: 37745051; PMCID: PMC10512468.
43.    Li N, Yang J, Wang C, Wu L, Liu Y. Screening bifunctional flavonoids of anticholinesterase and anti-glucosidase by in vitro and in silico studies: Quercetin, kaempferol and myricetin. Food Biosci. 2023; 51:102312. doi:10.1016/j.fbio.2022.102312.
44.    Cichon N, Grabowska W, Gorniak L, Stela M, Harmata P, Ceremuga M, Bijak M. Mechanistic and Therapeutic Insights into Flavonoid-Based Inhibition of Acetylcholinesterase: Implications for Neurodegenerative Diseases. Nutrients. 2024 Dec 28;17(1):78. doi: 10.3390/nu17010078. PMID: 39796512; PMCID: PMC11722824.
45.    Batiha GE, Beshbishy AM, Guswanto A, Nugraha A, Munkhjargal T, M Abdel-Daim M, et al. Phytochemical Characterization and Chemotherapeutic Potential of Cinnamomum verum Extracts on the Multiplication of Protozoan Parasites In Vitro and In Vivo. Molecules. 2020 Feb 24;25(4):996. doi: 10.3390/molecules25040996. PMID: 32102270; PMCID: PMC7070835. 
46.    Phu HH, Pham Van K, Tran TH, Pham DT. Extraction, chemical compositions, and biological activities of essential oils of Cinnamomum verum cultivated in Vietnam. Processes. 2022; 10(9):1713. doi: 10.3390/pr10091713.
47.    Dalai MK, Bhadra S, Chaudhary SK, Chanda J, Bandyopadhyay A, Mukherjee PK. Anticholinesterase activity of Cinnamomum zeylanicum L. leaf extract. Cell Med. 2014;4(2):11-1. doi: 10.5667/tang.2013.0034. 
48.    Durmaz L, Karageçili H, Erturk A, Ozden EM, Taslimi P, Alwasel S, et al. Hamamelitannin's antioxidant effect and its inhibition capability on α-glycosidase, carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase enzymes. Processes. 2024;12(11):2341. doi: 10.3390/pr12112341.
49.    Sharifi-Rad J, Dey A, Koirala N, Shaheen S, El Omari N, Salehi B, et al. Cinnamomum Species: Bridging Phytochemistry Knowledge, Pharmacological Properties and Toxicological Safety for Health Benefits. Front Pharmacol. 2021 May 11;12:600139. doi: 10.3389/fphar.2021.600139. PMID: 34045956; PMCID: PMC8144503.
50.    Boğa M, Hacıbekiroğlu I, Kolak U. Antioxidant and anticholinesterase activities of eleven edible plants. Pharm Biol. 2011 Mar;49(3):290-5. doi: 10.3109/13880209.2010.517539. Epub 2011 Feb 2. PMID: 21284538.
51.    Ghadami S, Saeedi M, Delnavazi MR, Eftekhari M, Edraki N, Akbarzadeh T, Khanavi MK. Oleo-gum-resin of Ferula persica: phytochemical analysis and enzyme inhibitory activity related to Alzheimer's disease. Res J Pharmacogn. 2024; 11(4): 39-48. doi: 10.22127/rjp.2024.454504.2438.
52.    Ota M, Houghton PJ. Boswellic acids with acetylcholinesterase inhibitory properties from frankincense. Nat Prod Commun. 2008;3(1):1934578X0800300105. doi: 10.1177/1934578X0800300105.
53.    Siddiqui A, Shah Z, Jahan RN, Othman I, Kumari Y. Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties. Biomed Pharmacother. 2021 Dec;144:112250. doi: 10.1016/j.biopha.2021.112250. Epub 2021 Oct 1. PMID: 34607104.
54.    Gupta M, Sharma C, Meena P, Khatri M. Investigating the free radical scavenging and acetylcholinesterase inhibition activities of Elletaria cardamomum, Piper nigrum and Syzygium aromaticum. Int J Pharm Sci Res. 2017; 8(7):3180-3186. doi:10.13040/IJPSR.0975-8232.8(7):
3180-86. 
55.    Pandey VK, Srivastava S, Ashish, Dash KK, Singh R, Dar AH, Singh T, Farooqui A, Shaikh AM, Kovacs B. Bioactive properties of clove (Syzygium aromaticum) essential oil nanoemulsion: A comprehensive review. Heliyon. 2023 Nov 30;10(1):e22437. doi: 10.1016/j.heliyon.2023.e22437. PMID: 38163240; PMCID: PMC10755278.
56.    Dalai MK, Bhadra S, Chaudhary SK, Bandyopadhyay A, Mukherjee PK. Anti-cholinesterase activity of the standardized extract of Syzygium aromaticum L. Pharmacogn Mag. 2014 Apr;10(Suppl 2):S276-82. doi: 10.4103/0973-1296.133275. PMID: 24991103; PMCID: PMC4078338.
57.    Kumar S, Brijeshlata DS, Dixit S. Screening of traditional Indian spices for inhibitory activity of acetylcholinesterase and butyrylcholinesterase enzymes. Int J Pharma Bio Sci. 2012; 3(1): 59-65.
58.    Ojo AB, Gyebi GA, Alabi O, Iyobhebhe M, Kayode AB, Nwonuma CO, et al. Syzygium aromaticum (L.) Merr. & LM Perry mitigates iron-mediated oxidative brain injury via in vitro, ex vivo, and in silico approaches. J Mol Struct. 2022;1268:133675. doi:10.1016/j.molstruc.2022.133675.
59.    Alimi D, Hajri A, Jallouli S, Sebai H. Toxicity, repellency, and anticholinesterase activities of bioactive molecules from clove buds Syzygium aromaticum L. as an ecological alternative in the search for control Hyalomma scupense (Acari: Ixodidae). Heliyon. 2023;9(8). doi: 10.1016/j.heliyon.2023.e18899. PMID: 37600394. PMCID: PMC10432207.
60.    Khwairakpam AD, Damayenti YD, Deka A, Monisha J, Roy NK, Padmavathi G, Kunnumakkara AB. Acorus calamus: a bio-reserve of medicinal values. J Basic Clin Physiol Pharmacol. 2018 Mar 28;29(2):107-122. doi: 10.1515/jbcpp-2016-0132. PMID: 29389665.
61.    Olas B, Bryś M. Is it safe to use Acorus calamus as a source of promising bioactive compounds in prevention and treatment of cardiovascular diseases? Chem Biol Interact. 2018 Feb 1;281:32-36. doi: 10.1016/j.cbi.2017.12.026. Epub 2017 Dec 19. PMID: 29273563.
62.    Malik R, Kalra S, Pooja, Singh G, Meenu, Gahlot V, et al. Antioxidative and neuroprotective potential of Acorus calamus linn. and Cordia dichotoma G. Forst. In Alzheimer's type dementia in rodent. Brain Res. 2024 Jan 1;1822:148616. doi: 10.1016/j.brainres.2023.148616. Epub 2023 Oct 2. PMID: 37793605.
63.    Kandikattu HK, Amruta N, Khanum F, Narayana VV, Srinivasulu D. A review on Cyperus rotundus: ancient weed to modern elixir of life phytochemistry and therapeutic uses of Cyperus rotundus (Mustaka). Pharm Biomed Res. 2021;7(4): 221-250. doi: 10.18502/pbr.v7i4.9369.  
64.    Davoudi F, Ramazani E. Antioxidant and anti-inflammatory effects of Cinnamomum species and their bioactive compounds: An updated review of the molecular mechanisms. Physiol Pharmacol. 2024;28(2):99-116. doi: 10.61186/phypha.28.2.99.
65.    Yu HS, Lee SY, Jang CG. Involvement of 5-HT1A and GABAA receptors in the anxiolytic-like effects of Cinnamomum cassia in mice. Pharmacol Biochem Behav. 2007 May;87(1):164-70. doi: 10.1016/j.pbb.2007.04.013. Epub 2007 May 4. PMID: 17512974. 
66.    Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer-Attali R, Peled S, et al. Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One. 2011 Jan 28;6(1):e16564. doi: 10.1371/journal.pone.0016564. PMID: 21305046; PMCID: PMC3030596.
67.    Oboh G, Ademiluyi AO, Akinyemi AJ. Inhibition of acetylcholinesterase activities and some pro-oxidant induced lipid peroxidation in rat brain by two varieties of ginger (Zingiber officinale). Exp Toxicol Pathol. 2012 May;64(4):315-9. doi: 10.1016/j.etp.2010.09.004. Epub 2010 Oct 16. PMID: 20952170.
68.    Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S, Korlakunta JN. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010 Feb 3;127(2):515-20. doi: 10.1016/j.jep.2009.10.004. Epub 2009 Oct 13. PMID: 19833188. 
69.    Pan Y, Li Z, Zhao X, Du Y, Zhang L, Lu Y, et al. Screening of Active Substances Regulating Alzheimer's Disease in Ginger and Visualization of the Effectiveness on 6-Gingerol Pathway Targets. Foods. 2024 Feb 18;13(4):612. doi: 10.3390/foods13040612. PMID: 38397589; PMCID: PMC10888025.
70.    Namazi Zadegan S, Ghayour-Mobarhan M, Hasheminejad SO, Shamsoddin Dayani M. Effects of eating frankincense, dates and quince during pregnancy and lactation on the mood, mental and behavorial health of children according to the Quran, Hadith and Medical Sciences. Iran J Obstet Gynecol Infertil. 2018;20(11):93-105. doi: 10.22038/ijogi.2018.10232.
71.    Ebrahimpour S, Fazeli M, Mehri S, Taherianfard M, Hosseinzadeh H. Boswellic Acid Improves Cognitive Function in a Rat Model Through Its Antioxidant Activity: - Neuroprotective effect of Boswellic acid. J Pharmacopuncture. 2017 Mar;20(1):10-17. doi: 10.3831/KPI.2017.20.001. PMID: 28392957; PMCID: PMC5374333.
72.    Haghaei H, Soltani S, Hosseini SA, Rashidi MR, Karima S. Boswellic acids as promising leads in drug development against Alzheimer's disease. Pharm Sci. 202018;27(1):14-31.doi:10.34172/PS.2020.25.
73.    Devaki M, Nirupama R, Nirupama M, Yajurvedi HN. Protective effect of rhizome extracts of the herb, vacha (Acorus calamus) against oxidative damage: An in vivo and in vitro study. Food Sci Hum Well. 2016;5(2):76-84. doi: 10.1016/j.fshw.2016.02.003.
74.    Mukherjee PK, Kumar V, Mal M, Houghton PJ. In vitro acetylcholinesterase inhibitory activity of the essential oil from Acorus calamus and its main constituents. Planta Med. 2007 Mar;73(3):283-5. doi: 10.1055/s-2007-967114. Epub 2007 Feb 7. PMID: 17286241.
75.    Baranifard M, Khazaei MM, Jamshidi S, Zarshenas MM, Zargaran A. A critical comparison between dosage forms in traditional Persian pharmacy and those reported in current pharmaceutical sciences. Res J Pharmacogn. 2017;4(3):67-74.
Trends in Pharmaceutical Sciences and Technologies
Volume 11, Issue 3
September 2025
Pages 235-252

Files

Share

How to cite

Statistics